Genomics Drug Discovery
PAYBACK Punkte
81 °P sammeln!
New, effective strategies for early assessment of drug toxicity and efficacyGenomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, pharmacogenetic, and toxicogenomic toolboxes, four promising and rapidly growing areas of genomics research that have begun opening the door to personalized medicine solutions. The authors thoroughly review and analyze all relevant technologies and analytical methods necessary for the competent design and execution of biomarker, pharmacogenomic, pharmacogenetic, and toxicogenomic studies. Moreover, by emphasizing the synerg...
New, effective strategies for early assessment of drug toxicity and efficacy
Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, pharmacogenetic, and toxicogenomic toolboxes, four promising and rapidly growing areas of genomics research that have begun opening the door to personalized medicine solutions. The authors thoroughly review and analyze all relevant technologies and analytical methods necessary for the competent design and execution of biomarker, pharmacogenomic, pharmacogenetic, and toxicogenomic studies. Moreover, by emphasizing the synergies among these areas, they arm pharmaceutical discovery scientists and drug development professionals with state-of-the-art strategies for reducing drug development time and costs, expediting a drug's approval, and improving its life cycle. Academic researchers will find in this book authoritative and integrated coverage of these rapidly developing and popular areas of genomic research.
Readers involved in laboratory, clinical, or modeling studies who are seeking to assess the toxicity and efficacy of drug candidates as early as possible can rely on this book to help guide their experiments. Topics include:
_ Weighing the relative advantages and disadvantages of available genomic technology platforms
_ Using pharmacogenomics and pharmacogenetics to position drug studies in the context of clinical trials
_ Identifying and validating biomarkers
_ Predicting and characterizing the toxicity of drugs
_ Applying study findings to improve the productivity of drug discovery
Today's pharmaceutical industry is characterized by exponentially rising R&D costs and a steadily decreasing percentage of approved drugs. Pharmaceutical discovery scientists therefore should take advantage of this book's unique integrated coverage of biomarkers, toxicogenomics, and pharmacogenomics in order to make their own discovery efforts as fruitful as possible.
Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, pharmacogenetic, and toxicogenomic toolboxes, four promising and rapidly growing areas of genomics research that have begun opening the door to personalized medicine solutions. The authors thoroughly review and analyze all relevant technologies and analytical methods necessary for the competent design and execution of biomarker, pharmacogenomic, pharmacogenetic, and toxicogenomic studies. Moreover, by emphasizing the synergies among these areas, they arm pharmaceutical discovery scientists and drug development professionals with state-of-the-art strategies for reducing drug development time and costs, expediting a drug's approval, and improving its life cycle. Academic researchers will find in this book authoritative and integrated coverage of these rapidly developing and popular areas of genomic research.
Readers involved in laboratory, clinical, or modeling studies who are seeking to assess the toxicity and efficacy of drug candidates as early as possible can rely on this book to help guide their experiments. Topics include:
_ Weighing the relative advantages and disadvantages of available genomic technology platforms
_ Using pharmacogenomics and pharmacogenetics to position drug studies in the context of clinical trials
_ Identifying and validating biomarkers
_ Predicting and characterizing the toxicity of drugs
_ Applying study findings to improve the productivity of drug discovery
Today's pharmaceutical industry is characterized by exponentially rising R&D costs and a steadily decreasing percentage of approved drugs. Pharmaceutical discovery scientists therefore should take advantage of this book's unique integrated coverage of biomarkers, toxicogenomics, and pharmacogenomics in order to make their own discovery efforts as fruitful as possible.
Andere Kunden interessierten sich für
